Tests an algae powder for vision in teens with retinitis pigmentosa
Tests an algae powder against a starch placebo in teens with retinitis pigmentosa.
Plain-language title generated from the registry record
Registry title: The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa
Key facts
- Where
- Tel HaShomer, IsraelSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Source: NCT02018692, who can take part
Where in Israel
- Goldschleger Eye Research Institute, Sheba Medical Center,Tel HaShomer, IsraelNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sheba Medical Center
- Trial code
- NCT02018692
- Record updated
- 6 October 2025
- Original description
The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.Read full original descriptionShow less
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa
The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.
Inclusion: Written informed consent to participate in the study; Adolescent 12-18 years old; Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa.
Exclusion: Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery; Participation in another investigational drug study within 4 weeks prior to enrolment; Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment; History of malignancy, excepting basal or squamous cell skin carcinoma; Uncontrolled hypertension, defined either as resting diastolic blood pressure >95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure >180 mmHg; History of alcohol abuse or drug abuse or both; Uncontrolled endocrine or metabolic disease; Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study; Currently a smoker; Current use of vitamin A/ β-carotene supplements; Females who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception; Intention to engage in vigorous exercise or an aggressive diet regimen.